Oryzon Genomics announced the presentation of promising updates for two clinical studies involving iadademstat at the American Society of Hematology (ASH) 67th Annual Meeting. Notably, a Phase Ib trial (ALICE-2) testing the candidate in combination with azacitidine and venetoclax showed a 100% over
